By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282



Company News
Immunomedics, Inc. (IMMU) Reports Interim Phase II Results With Sacituzumab Govitecan In Lung Cancers 9/8/2015 7:57:49 AM
Immunomedics, Inc. (IMMU) To Present At Upcoming Investor Conferences 9/2/2015 7:29:21 AM
Immunomedics, Inc. (IMMU) Appoints Arthur S. Kirsch As Director 8/19/2015 7:50:30 AM
Immunomedics, Inc. (IMMU) Extends U.S. Patent Protection For Antibody-Drug Conjugate Program To 2033 8/18/2015 8:16:24 AM
Immunomedics, Inc. (IMMU) Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2015 Financial Results 8/14/2015 10:14:57 AM
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Immune Thrombocytopenia 8/4/2015 7:21:11 AM
Immunomedics, Inc. (IMMU) CEO, William Hearl, Ph.D. To Speak At 2015 BIO International Convention 6/3/2015 12:39:45 PM
Immunomedics, Inc. (IMMU) Reports Labetuzumab Govitecan Is Active In Relapsed Metastatic Colorectal Cancer 6/2/2015 10:17:05 AM
Immunomedics, Inc. (IMMU) Announces Durable Responses In Metastatic Lung Cancer Patients Treated With Sacituzumab Govitecan 6/2/2015 8:38:26 AM
ASCO15: Immunomedics, Inc. (IMMU) Reports Complete Responses In Patients With Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment 6/1/2015 10:31:15 AM